166 related articles for article (PubMed ID: 29780852)
1. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.
Isaacson SH; Fahn S; Pahwa R; Tanner CM; Espay AJ; Trenkwalder C; Adler CH; Patni R; Johnson R
Mov Disord Clin Pract; 2018; 5(2):183-190. PubMed ID: 29780852
[TBL] [Abstract][Full Text] [Related]
2. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Hauser RA; Pahwa R; Tanner CM; Oertel W; Isaacson SH; Johnson R; Felt L; Stempien MJ
J Parkinsons Dis; 2017; 7(3):511-522. PubMed ID: 28777755
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
4. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Tanner CM; Pahwa R; Hauser RA; Oertel WH; Isaacson SH; Jankovic J; Johnson R; Chernick D; Hubble J
J Parkinsons Dis; 2020; 10(2):543-558. PubMed ID: 31929122
[TBL] [Abstract][Full Text] [Related]
5. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
[TBL] [Abstract][Full Text] [Related]
6. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Pahwa R; Tanner CM; Hauser RA; Isaacson SH; Nausieda PA; Truong DD; Agarwal P; Hull KL; Lyons KE; Johnson R; Stempien MJ
JAMA Neurol; 2017 Aug; 74(8):941-949. PubMed ID: 28604926
[TBL] [Abstract][Full Text] [Related]
7. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O; Tönges L; deVries T; Jaros M; Quartel A; Jacobs D;
Parkinsonism Relat Disord; 2022 Mar; 96():65-73. PubMed ID: 35227940
[TBL] [Abstract][Full Text] [Related]
8. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Elmer LW; Juncos JL; Singer C; Truong DD; Criswell SR; Parashos S; Felt L; Johnson R; Patni R
CNS Drugs; 2018 Apr; 32(4):387-398. PubMed ID: 29532440
[TBL] [Abstract][Full Text] [Related]
9. Amantadine Extended-Release (GOCOVRI
Paik J; Keam SJ
CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
[TBL] [Abstract][Full Text] [Related]
10. Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.
Mehta SH; Pahwa R; Tanner CM; Hauser RA; Johnson R
Neurol Ther; 2021 Jun; 10(1):307-320. PubMed ID: 33864229
[TBL] [Abstract][Full Text] [Related]
11. Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia.
Hauser RA; Mehta SH; Kremens D; Chernick D; Formella AE
Neurol Ther; 2021 Dec; 10(2):739-751. PubMed ID: 34024025
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
Hauser RA; Pahwa R; Wargin WA; Souza-Prien CJ; McClure N; Johnson R; Nguyen JT; Patni R; Went GT
Clin Pharmacokinet; 2019 Jan; 58(1):77-88. PubMed ID: 29777529
[TBL] [Abstract][Full Text] [Related]
13. Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy.
Hauser RA; Goud S; Formella AE
Clin Park Relat Disord; 2022; 6():100123. PubMed ID: 35059622
[TBL] [Abstract][Full Text] [Related]
14. Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
Pahwa R; Isaacson S; Jimenez-Shaheed J; Malaty IA; Deik A; Johnson R; Patni R
Parkinsonism Relat Disord; 2019 Mar; 60():118-125. PubMed ID: 30292734
[TBL] [Abstract][Full Text] [Related]
15. Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.
Hauser RA; Lytle J; Formella AE; Tanner CM
NPJ Parkinsons Dis; 2022 Mar; 8(1):29. PubMed ID: 35304480
[TBL] [Abstract][Full Text] [Related]
16. Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia.
Pahwa R; Fox S; Hauser RA; Isaacson S; Lytle J; Johnson R; Llorens L; Formella AE; Tanner CM
Front Neurol; 2022; 13():846126. PubMed ID: 36341088
[TBL] [Abstract][Full Text] [Related]
17. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Elkurd MT; Bahroo LB; Pahwa R
Neurodegener Dis Manag; 2018 Apr; 8(2):73-80. PubMed ID: 29564954
[TBL] [Abstract][Full Text] [Related]
18. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Ory-Magne F; Corvol JC; Azulay JP; Bonnet AM; Brefel-Courbon C; Damier P; Dellapina E; Destée A; Durif F; Galitzky M; Lebouvier T; Meissner W; Thalamas C; Tison F; Salis A; Sommet A; Viallet F; Vidailhet M; Rascol O;
Neurology; 2014 Jan; 82(4):300-7. PubMed ID: 24371304
[TBL] [Abstract][Full Text] [Related]
19. Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.
Sharma VD; Lyons KE; Pahwa R
Ther Clin Risk Manag; 2018; 14():665-673. PubMed ID: 29695911
[TBL] [Abstract][Full Text] [Related]
20. Extended-release amantadine for OFF-related dystonia in Parkinson's disease.
Espay AJ; Ostrem JL; Formella AE; Tanner CM
Parkinsonism Relat Disord; 2024 May; 122():106088. PubMed ID: 38461688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
